A patient-centric biopharmaceutical company advancing potent and selective small molecule modulators to address unmet medical needs in oncology and autoimmune diseases.
With an advanced discovery engine which integrates structure-based design and computational algorithms to discover and develop novel, precision therapeutics against both first-in-class and validated but intractable targets in genetically-defined patient populations.
Striving for speed and efficiency by employing a business model that leverages the proven and synergistic capabilities of Jubilant Pharmova Limited's value chain and shared services.
Headquartered in Bedminster, New Jersey (U.S.) and guided by globally renowned key opinion leaders and scientific advisory board members.